Data Insights

Cadonilimab by Akeso for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Cadonilimab by Akeso for Metastatic Pancreatic Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Metastatic Pancreatic Cancer

Data Insights

Cadonilimab by Akeso for Small-Cell Lung Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Small-Cell Lung Cancer

Data Insights

Cadonilimab by Akeso for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Cadonilimab by Akeso for Non-Small Cell Lung Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Non-Small Cell Lung Cancer

Data Insights

Cadonilimab by Akeso for Gastric Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Gastric Cancer

Data Insights

Cadonilimab by Akeso for Colorectal Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Colorectal Cancer

Data Insights

Cadonilimab by Akeso for Epithelial Ovarian Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Epithelial Ovarian Cancer

Data Insights

Cadonilimab by Akeso for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Cadonilimab by Akeso for Squamous Non-Small Cell Lung Carcinoma: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Squamous Non-Small Cell Lung Carcinoma

Data Insights

Cadonilimab by Akeso for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

Cadonilimab by Akeso for Rectal Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Rectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Rectal Cancer

Data Insights

Cadonilimab by Akeso for Vulvar Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Vulvar Cancer

Data Insights

Cadonilimab by Akeso for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Cadonilimab by Akeso for Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma): Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma)

Data Insights

Cadonilimab by Akeso for Signet Ring Cell Squamous Cell Carcinoma: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Signet Ring Cell Squamous Cell Carcinoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Signet Ring Cell Squamous Cell Carcinoma

Data Insights

Cadonilimab by Akeso for Metastatic Biliary Tract Cancer: Likelihood of Approval

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Metastatic Biliary Tract Cancer